Genmab loses appeal in Darzalex royalties arbitration case against Johnson & Johnson

While sales for Johnson & Johnson’s Darzalex continue to boom—as the company reported in its quarterly earnings presentation on Tuesday—the pharma major got more good news about its blockbuster multiple myeloma treatment with a victory in an arbitration case.